Seizure control is everything. Well-controlled epilepsy often qualifies for standard rates. Here's the complete picture — from seizure-free status to genetic causes.
📅 Updated November 2026⏱️ 10 min read⚡ Seizure control is the key variable
🧬
Reviewed by the DNAPolicy.org Editorial Team
Our life insurance guides are reviewed for accuracy by licensed insurance professionals and cross-referenced with current underwriting guidelines. Content is updated regularly to reflect industry changes. Last reviewed: November 2026
The Single Most Important Factor: Seizure-Free Status
In epilepsy underwriting, how long you've been seizure-free on stable medication is the dominant variable. 2+ years seizure-free significantly opens up traditional coverage options. The longer the seizure-free period, the lower the table rating. If you've recently had a breakthrough seizure, consider waiting to reestablish seizure-free status before applying.
Epilepsy Insurance Impact Tool
Enter your epilepsy profile to see your underwriting outlook.
Est. monthly ($500K / 20yr term)
$30/mo
Seizure-free period status
✅ Good
Underwriting outlook
2–5 years seizure-free. Standard to Table B at most carriers. Single AED with stability is favorable. Shop multiple carriers.
Estimates for healthy non-smoker, idiopathic epilepsy. Actual rates vary by carrier, seizure type, and complete medical profile.
Seizure Control and Underwriting Outcomes
Seizure-free 5+ years, single AED, stable
Standard to Table A at most carriers
Seizure-free 2–5 years, stable medication
Standard to Table B — depends on carrier and seizure type
Seizure-free 1–2 years, stable medication
Table A–C — carriers want longer seizure-free period
Seizure-free < 1 year or recent breakthrough
Table C–E or possible decline; simplified issue viable
Active seizures, poorly controlled
Most traditional carriers decline; simplified/GI primary
Status epilepticus history (< 2 years)
Traditional typically unavailable; guaranteed issue available
The Genetics of Epilepsy
Approximately 30–40% of epilepsy cases have a significant genetic component. Over 500 epilepsy-related genes have been identified. The most clinically important:
SCN1A
Sodium channel Nav1.1
The most commonly mutated gene in epilepsy. Mutations cause Dravet syndrome — a severe, treatment-resistant childhood epilepsy — and GEFS+ (generalized epilepsy with febrile seizures plus). SCN1A testing is now standard in childhood epilepsy workups.
KCNQ2 / KCNQ3
Potassium channel genes
Mutations cause neonatal seizures — typically benign and self-resolving. KCNQ2 is associated with both benign neonatal epilepsy and more severe epileptic encephalopathy depending on the specific variant.
CDKL5
Cyclin-dependent kinase-like 5
X-linked gene causing CDKL5 deficiency disorder — early-onset, treatment-resistant seizures primarily in females. One of the more common causes of Rett syndrome-like features.
PCDH19
Protocadherin-19
Unusual X-linked inheritance pattern where heterozygous females are affected but hemizygous males are not. Causes female-limited epilepsy — a cluster pattern of brief seizures often triggered by fever.
Insurance implications: Life insurers underwrite epilepsy based on seizure control, medication stability, and clinical history — not genetic variants. A genetic epilepsy syndrome that is well-controlled is underwritten based on the control, not the gene. GINA and life insurance →
Common AEDs and Underwriting Notes
Medication
Common Brand
Underwriting Notes
Levetiracetam
Keppra
✅ Well-tolerated, clean lab profile — favorable signal
Lamotrigine
Lamictal
✅ Common first-line — favorable, minimal lab impact
Valproic acid / divalproex
Depakote
⚠️ Liver enzyme elevation (ALT/AST) common; low platelets possible — will be noted
Carbamazepine
Tegretol
⚠️ CBC and liver enzymes affected — hyponatremia possible
Oxcarbazepine
Trileptal
⚠️ Similar to carbamazepine; hyponatremia risk
Phenytoin
Dilantin
⚠️ Older drug — CBC, liver, and gingival effects noted; suggests long-standing epilepsy
Topiramate
Topamax
✅ Generally clean; kidney stone risk with long-term use
Zonisamide
Zonegran
✅ Generally clean lab profile
Phenobarbital
Luminal
⚠️ Older drug, sedating — may signal harder-to-control or long-standing epilepsy
Clobazam / clonazepam
Onfi / Klonopin
⚠️ Benzodiazepine class — dependence potential noted; suggests adjunct treatment for harder-to-control epilepsy
Yes — many people with epilepsy can get life insurance, though the type, cost, and availability depend heavily on seizure control, seizure type, frequency, and underlying cause. Well-controlled epilepsy — no seizures in 2+ years on stable medication — often qualifies for standard to mildly table-rated traditional coverage. Poorly controlled or frequent seizures, or epilepsy caused by an underlying brain condition, results in more restrictive underwriting. Simplified and guaranteed issue options are available for anyone with epilepsy regardless of control status.
What is "seizure-free" and why does it matter for underwriting?
Seizure-free status is the single most important factor in epilepsy underwriting. Underwriters want to see a documented period of no seizures — typically 2 years minimum for the most favorable rates. The longer you've been seizure-free on a stable medication regimen, the lower the perceived mortality risk. Someone seizure-free for 5+ years on a single AED at a stable dose is underwritten significantly more favorably than someone who had a breakthrough seizure 6 months ago. If you've recently changed medications or had a breakthrough seizure, consider waiting until you've reestablished seizure-free status before applying for traditional coverage.
Does the type of epilepsy or seizure affect my insurance?
Yes — significantly. Focal (partial) seizures with limited spread and no loss of consciousness are viewed more favorably than generalized tonic-clonic (grand mal) seizures. Absence seizures (petit mal) in children who have outgrown them are often not an underwriting issue at all. Juvenile myoclonic epilepsy (JME) — which is lifelong but typically well-controlled — is underwritten case by case. Status epilepticus (prolonged seizures requiring emergency treatment) in history is a significant negative flag. Epilepsy caused by a known structural cause (prior brain injury, tumor, stroke) is underwritten based on both the epilepsy AND the underlying cause.
Will my antiepileptic drugs (AEDs) affect my life insurance application?
Antiepileptic drugs themselves are not a negative underwriting factor — they signal that your condition is being treated. Underwriters evaluate the number of medications (one AED at stable dose = better; multiple or frequently changed = may signal harder-to-control epilepsy), dosage stability (unchanged dose for 1+ years = positive), and any significant side effects. Some AEDs have drug interactions or organ effects that show up in bloodwork: valproic acid/divalproex can cause liver enzyme elevation (ALT/AST) and low platelets; carbamazepine and phenytoin can affect CBC and liver enzymes. Underwriters will note these when reviewing medical exam results.
What if I had epilepsy as a child that I've grown out of?
Childhood epilepsy that has fully resolved — particularly benign childhood epilepsy with centrotemporal spikes (BECTS/Rolandic epilepsy) or simple febrile seizures — is generally viewed very favorably. If you've been seizure-free for 5+ years without medication and your neurologist has confirmed the epilepsy has resolved, most carriers will offer standard rates. Disclose the history accurately and provide documentation of the resolution. This is very different from ongoing epilepsy requiring medication.
What is SUDEP and how does it affect life insurance underwriting?
SUDEP (Sudden Unexpected Death in Epilepsy) is a known mortality risk in epilepsy — it accounts for approximately 7-17% of deaths in people with epilepsy, and risk is higher in those with uncontrolled seizures, particularly nighttime generalized tonic-clonic seizures. Life insurance underwriters are aware of SUDEP risk. This is part of why seizure control is so important in underwriting — controlled epilepsy has a significantly lower SUDEP risk than uncontrolled. Seizure-free status directly reduces the SUDEP risk factor that underwriters price for.
What if I have both epilepsy and intellectual disability?
The combination of epilepsy with intellectual disability (ID) — which co-occurs in approximately 20-30% of people with epilepsy — represents a more complex underwriting situation. Traditional term and whole life insurance is typically very difficult to obtain for applicants with significant intellectual disability, regardless of epilepsy status. Simplified issue may be possible depending on the degree of disability. Guaranteed issue whole life is available to anyone. Some carriers have specific programs for individuals with disabilities — a disability insurance specialist may be helpful in identifying these options.
What if I had a single unprovoked seizure — do I have epilepsy for insurance purposes?
A single unprovoked seizure is treated differently from a diagnosed epilepsy. Life insurance applications typically ask if you've been diagnosed with epilepsy or a seizure disorder. A single seizure that was investigated, found to have no ongoing structural cause, and has not recurred in 2+ years may not result in an epilepsy designation in your records. However, if you are on antiepileptic medication following a single seizure, underwriters will want to understand the full picture. Disclose accurately and let underwriters evaluate — don't assume a single past seizure results in automatic decline.
Seizure-free means insurable.
Two years seizure-free on stable medication opens traditional coverage at most carriers. Know your seizure-free date — it's your most valuable underwriting asset.